Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: An AIDS malignancy consortium study of sunitinib in patients on ART
| Autor: | John F. Deeken, S. P. Ivy, Richard F. Little, B. J. Dezube, Page C. Moore, K. Mosby, Ronald T. Mitsuyasu, Jeannette Y. Lee, M. A. Rudek, R. F. Ambinder |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy AIDS Malignancy Consortium Sunitinib business.industry Incidence (epidemiology) medicine.medical_treatment Prodrug medicine.disease Lymphoma Acquired immunodeficiency syndrome (AIDS) Internal medicine Immunology medicine In patient business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 28:TPS161-TPS161 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2010.28.15_suppl.tps161 |
| Popis: | TPS161 Background: The cumulative NADC incidence is approaching that of AIDS-defining cancers in HIV-infected persons in populations where effective antiretroviral therapy (ART) is commonly used. Marked increases in risk are seen in certain cancers, including lung, liver, head and neck, anogenital, and Hodgkin's lymphoma. Treatment of NADCs may be complicated by drug-drug interactions between ART and chemotherapy, including ART-mediated induction or inhibition of metabolizing enzymes, especially of the CYP450 family. To study these interactions, with the goal of formulating treatment recommendations on the use of targeted anticancer agents to treat NADCs in HIV+ patients, the AIDS Malignancy Consortium has launched the first clinical study to address this emerging epidemic. Sunitinib is a multi-targeted TKI of PDGFR, VEGFR1/3, KIT, FLT3, SCF, and RET. It is a prodrug which is metabolized into the active metabolite SU012662 by CYP3A4, which is then further inactivated by CYP3A4. Methods: The primary object... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|